Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Gains from Sales and Divestitures (2020 - 2025)

Protalix BioTherapeutics (PLX) has 6 years of Gains from Sales and Divestitures data on record, last reported at $52910.0 in Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures changed N/A year-over-year to $52910.0; the TTM value through Sep 2025 reached $52910.0, changed N/A, while the annual FY2024 figure was $992313.0, 102.86% up from the prior year.
  • Gains from Sales and Divestitures reached $52910.0 in Q3 2025 per PLX's latest filing, down from $992313.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $992313.0 in Q4 2024 and bottomed at $52910.0 in Q3 2025.
  • Average Gains from Sales and Divestitures over 5 years is $525395.4, with a median of $489166.0 recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: skyrocketed 456.0% in 2022, then crashed 47.18% in 2023.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $166553.0 in 2021, then surged by 456.0% to $926035.0 in 2022, then plummeted by 47.18% to $489166.0 in 2023, then skyrocketed by 102.86% to $992313.0 in 2024, then crashed by 94.67% to $52910.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $52910.0 in Q3 2025, $992313.0 in Q4 2024, and $489166.0 in Q4 2023.